Reviva Pharmaceuticals Hldg Inc (RVPH)

$0.41 +0.02 (5.58%)
Market Cap 18.70M
Revenue (ttm) 0.00
Net Income (ttm) -29.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,737,600
Avg Vol 1,866,566
Day's Range N/A - N/A
Shares Out 48.00M
Stochastic %K 26%
Beta -0.06
Analysts Strong Sell
Price Target $9.43

Company Profile

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity...

Industry: Biotechnology
Sector: Healthcare
Phone: 408-501-8881
Fax: 408-904-6270
Address:
10080 N. Wolfe Road, Suite SW3-200, Cupertino, United States
channelsurfer
channelsurfer Jul. 17 at 8:54 PM
$RVPH 10% float bought at $.38 and above the last 3 days 👍
0 · Reply
channelsurfer
channelsurfer Jul. 17 at 4:36 PM
$RVPH trying to stand up again 👍
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jul. 17 at 1:35 AM
$RVPH I think Bhat is in for a sex change right now and really is playing with himself and the investors.
2 · Reply
HjalmarTheGreat
HjalmarTheGreat Jul. 17 at 12:56 AM
$RVPH Pull yourselves up by your bootstraps, campers! Jeez. 🤣
0 · Reply
Liondog
Liondog Jul. 16 at 8:32 PM
$RVPH lax doesn’t care once him and his wife gets paid he’s ok with this company failing
0 · Reply
okhello1
okhello1 Jul. 16 at 7:18 PM
$RVPH I have a question. Is the company in the suspension period for the share under $1?
1 · Reply
Bigms888
Bigms888 Jul. 16 at 5:15 PM
$RVPH
0 · Reply
Mkt_predictor
Mkt_predictor Jul. 16 at 2:04 PM
$RVPH Still a huge turd. how is Lax really this incompetent? its truly amazing.
0 · Reply
Bucky712
Bucky712 Jul. 15 at 6:54 PM
$RVPH Yuge reversal. Load the boat 💰💰💰
0 · Reply
DonkeyPuncherDude
DonkeyPuncherDude Jul. 15 at 3:29 PM
$RVPH Ya, ppl running for the hills and dumping this trash. Lazy Lax is working hard for us tho 🤣🤣🤣
1 · Reply
Latest News on RVPH
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Jun 26, 2025, 8:40 AM EDT - 21 days ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Jun 25, 2025, 4:17 PM EDT - 22 days ago

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 5, 2025, 8:00 AM EDT - 6 weeks ago

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Jun 2, 2025, 7:00 AM EDT - 6 weeks ago

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025, 4:05 PM EDT - 2 months ago

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Mar 30, 2025, 11:30 AM EDT - 3 months ago

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:00 AM EST - 5 months ago

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Jan 30, 2025, 8:00 AM EST - 6 months ago

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Jan 7, 2025, 8:00 AM EST - 6 months ago

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Reviva Announces Proposed Public Offering

Dec 16, 2024, 5:18 PM EST - 7 months ago

Reviva Announces Proposed Public Offering

Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low

Dec 11, 2024, 3:37 PM EST - 7 months ago

Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 5:25 PM EST - 8 months ago

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Nov 6, 2024, 8:00 AM EST - 9 months ago

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Reviva to Participate in the UBS Global Healthcare Conference

Oct 31, 2024, 8:00 AM EDT - 9 months ago

Reviva to Participate in the UBS Global Healthcare Conference

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 8, 2024, 8:00 AM EDT - 10 months ago

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024, 8:30 AM EDT - 10 months ago

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

Aug 21, 2024, 6:00 AM EDT - 11 months ago

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 29, 2024, 4:45 PM EDT - 1 year ago

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 28, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Reviva to Participate in the BIO International Convention

May 21, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the BIO International Convention

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

May 15, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 14, 2024, 8:00 AM EDT - 1 year ago

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

May 13, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

May 9, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

Apr 15, 2024, 8:30 AM EDT - 1 year ago

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

Apr 15, 2024, 8:05 AM EDT - 1 year ago

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

Reviva to Present at the UBS Virtual CNS Day

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present at the UBS Virtual CNS Day

Reviva to Present at the 36th Annual ROTH Conference

Mar 7, 2024, 8:00 AM EST - 1 year ago

Reviva to Present at the 36th Annual ROTH Conference

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 20, 2024, 8:00 AM EST - 1 year ago

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Feb 6, 2024, 8:00 AM EST - 1 year ago

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

Jan 25, 2024, 8:00 AM EST - 1 year ago

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

Jan 10, 2024, 8:00 AM EST - 1 year ago

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Jan 4, 2024, 8:00 AM EST - 1 year ago

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

Dec 11, 2023, 8:00 AM EST - 1 year ago

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Nov 30, 2023, 4:05 PM EST - 1 year ago

Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 20, 2023, 4:05 PM EST - 1 year ago

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 16, 2023, 8:00 AM EST - 1 year ago

Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 14, 2023, 4:01 PM EST - 1 year ago

Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started

Nov 2, 2023, 3:11 AM EDT - 1 year ago

Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started

Reviva Pharma's schizophrenia drug succeeds in late-stage study

Oct 30, 2023, 7:41 AM EDT - 1 year ago

Reviva Pharma's schizophrenia drug succeeds in late-stage study

Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Oct 30, 2023, 7:30 AM EDT - 1 year ago

Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

Sep 29, 2023, 9:00 AM EDT - 1 year ago

Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

AREC STSS

Reviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVER

Sep 27, 2023, 2:48 AM EDT - 1 year ago

Reviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVER

Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia

Sep 25, 2023, 6:00 AM EDT - 1 year ago

Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia

Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

Sep 22, 2023, 1:30 PM EDT - 1 year ago

Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

channelsurfer
channelsurfer Jul. 17 at 8:54 PM
$RVPH 10% float bought at $.38 and above the last 3 days 👍
0 · Reply
channelsurfer
channelsurfer Jul. 17 at 4:36 PM
$RVPH trying to stand up again 👍
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jul. 17 at 1:35 AM
$RVPH I think Bhat is in for a sex change right now and really is playing with himself and the investors.
2 · Reply
HjalmarTheGreat
HjalmarTheGreat Jul. 17 at 12:56 AM
$RVPH Pull yourselves up by your bootstraps, campers! Jeez. 🤣
0 · Reply
Liondog
Liondog Jul. 16 at 8:32 PM
$RVPH lax doesn’t care once him and his wife gets paid he’s ok with this company failing
0 · Reply
okhello1
okhello1 Jul. 16 at 7:18 PM
$RVPH I have a question. Is the company in the suspension period for the share under $1?
1 · Reply
Bigms888
Bigms888 Jul. 16 at 5:15 PM
$RVPH
0 · Reply
Mkt_predictor
Mkt_predictor Jul. 16 at 2:04 PM
$RVPH Still a huge turd. how is Lax really this incompetent? its truly amazing.
0 · Reply
Bucky712
Bucky712 Jul. 15 at 6:54 PM
$RVPH Yuge reversal. Load the boat 💰💰💰
0 · Reply
DonkeyPuncherDude
DonkeyPuncherDude Jul. 15 at 3:29 PM
$RVPH Ya, ppl running for the hills and dumping this trash. Lazy Lax is working hard for us tho 🤣🤣🤣
1 · Reply
builderup
builderup Jul. 15 at 9:57 AM
New watchlist: Names you don’t see everyday. Let’s go! $TLPH $BDMD $RVPH $PBYI - swing play
0 · Reply
yellowdog11
yellowdog11 Jul. 14 at 3:49 PM
$RVPH Looking good here Glad I got a bunch more in the 30's Good volume and nice steady price increase woof
0 · Reply
azonic
azonic Jul. 14 at 3:40 PM
$RVPH shes winding up
1 · Reply
Bucky712
Bucky712 Jul. 14 at 2:53 PM
$RVPH Super bullish moving forward. This reminds me of $CLDI. Rising from the ashes and then blasting off. Get on board.
3 · Reply
Tushar1
Tushar1 Jul. 14 at 2:53 PM
$RVPH
1 · Reply
Tushar1
Tushar1 Jul. 14 at 2:38 PM
$RVPH dark pool activity started $2
0 · Reply
azonic
azonic Jul. 14 at 2:30 PM
$RVPH running incoming boys
0 · Reply
Liondog
Liondog Jul. 14 at 8:22 AM
$RVPH still nothing to get investors excited I’ve said it before and I’ll say it again lax shouldn’t be running a company he should be in a lab working for someone
0 · Reply
Shalleyliu
Shalleyliu Jul. 11 at 3:14 PM
$RVPH Accord to the top 10 with estimated timeline, by the end of July, Reviva will announce the partnership and results of meeting with FDA for NDA submission. Hopefully we will get positive news on one thing
4 · Reply
Jlloyd31
Jlloyd31 Jul. 10 at 2:13 PM
$RVPH on pump watch. $ABVE
0 · Reply
Tushar1
Tushar1 Jul. 10 at 2:04 PM
$RVPH
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jul. 10 at 1:07 PM
$RVPH have a read: Tang owns over 10% of RVPH. https://www.sfgate.com/tech/article/fund-gobbling-bay-area-biotech-20761986.php
1 · Reply